China Diabetes Devices Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

China's diabetes devices market encompasses blood glucose monitors, continuous glucose monitoring (CGM) systems, insulin pumps, insulin pens, and digital diabetes management platforms. The market has grown from an estimated $1.73 billion in 2023 to approximately $4.52 billion in 2025, reflecting significant investment in diabetes care infrastructure. Long-term forecasts project continued expansion, with the broader China diabetes market expected to approach $9.89 billion by 2034 at a 6.73% CAGR.

• •Market valued at approximately $4.52 billion in 2025, up from $1.73 billion in 2023
• •Projected to reach nearly $9.76 billion by 2030 according to some industry analyses
• •Estimated CAGR range across sources: 5.3% to 9.11%

China has one of the world's largest diabetic populations, with prevalence rising due to urbanization, dietary shifts, and an aging demographic. Government initiatives under the Healthy China 2030 plan have expanded insurance coverage for diabetes management devices and treatments, improving patient access. The proliferation of digital health platforms and telemedicine services has accelerated adoption of connected glucose monitoring and remote patient management solutions.

• •Rising diabetes prevalence driven by urbanization, sedentary lifestyles, and aging population
• •Healthy China 2030 policy framework expanding reimbursement for diabetes management technologies
• •Growing middle class and increased healthcare spending enabling greater device adoption

The market spans insulin delivery devices, blood glucose monitoring devices, and digital diabetes management systems, with the digital segment projected to grow at a 10.2% CAGR through 2030. Within the broader Asia Pacific diabetes care devices market, China accounted for 38.5% of regional revenue in 2024, far outpacing other nations in the region. The Asia Pacific insulin delivery devices segment alone reached $6.1 billion in 2025, with China identified as the primary growth engine driving a 10.6% CAGR.

• •China held 38.5% of Asia Pacific diabetes care devices revenue share in 2024
• •Digital diabetes management segment projected to reach $5.24 billion by 2030 at 10.2% CAGR
• •Asia Pacific insulin delivery devices market valued at $6.1 billion in 2025, growing at 10.6% CAGR

What are the recent trends and outlook?

Continuous glucose monitoring adoption is accelerating as prices decline and insurance coverage expands, shifting market share away from traditional finger-prick testing methods. Digital health integration, including mobile apps, cloud-based data platforms, and AI-driven insights, is becoming a key differentiator among device manufacturers. The market is expected to sustain its 7.37% annual growth trajectory through the decade as next-generation wearable sensors, closed-loop insulin delivery systems, and telemedicine-enabled diabetes management become mainstream.

• •CGM adoption accelerating as device costs decline and reimbursement expands in China
• •AI-powered digital diabetes management and connected health platforms emerging as competitive advantages
• •Next-generation wearable sensors and closed-loop insulin delivery systems gaining clinical traction